Samsung Electronics and SK Hynix Are Still Buy Territory… Why Going All-In on Semiconductors Is Risky | Lee Jae-kyu, SK Securities PB Deputy General Manager

삼전닉스 아직 매수 구간…그래도 반도체에 ‘몰빵’하면 위험한 이유ㅣ이재규 SK증권 PB 차장 [집중 오늘의 주식]
Watch on YouTube ↗  |  August 24, 2026 at 12:00  |  40:03  |  3PRO TV (삼프로TV)
Speakers
Lee Jae-kyu — PB Deputy Manager, SK Securities

Summary

SK Securities PB Lee Jae-kyu discusses why investors should refresh their portfolios rather than stay concentrated in Samsung Electronics and SK Hynix. He still views Samsung Electronics, SK Hynix and Korean semiconductors as buy-on-dip but says concentration is risky, and he highlights rotation into food and cosmetics, KOSDAQ ETFs, secondary batteries and ESS, Hanmi Pharm, and biotech and pharma. He also stresses cash management and using ETFs given fast rotation and high volatility.

  • Market remains volatile but KOSPI and KOSDAQ breadth is improving and rotation is broadening beyond semiconductors.
  • Samsung Electronics, SK Hynix and Samsung Electronics preferred shares are seen as buy-on-dip despite the pullback.
  • Concentrating heavily in semiconductors is seen as risky; lower-tier semis are also attractive if trend support holds.
  • KOSDAQ is viewed positively if relative strength persists through September 6, preferably via ETFs.
  • Secondary batteries and ESS are seen as benefiting from AI data center security, US-China restrictions and possible shortages.
  • Hanmi Pharm and broader biotech and pharma are highlighted as areas to watch, with ETF access recommended.
  • Food and cosmetics names such as Korea Kolmar, Samyang Foods and Binggrae may signal an asset allocation rotation.
Ideas
Lee Jae-kyu PB Deputy Manager, SK Securities 3:19
KOSPI likely rebounds if US stable.
Foreign investors lifted KOSPI futures late in the session; if the US market does not fall sharply overnight, the Korean market may rebound to some extent the next day, but this is a short-term tactical setup dependent on US stability.
Lee Jae-kyu PB Deputy Manager, SK Securities 9:18
Rotation into food and cosmetics emerging.
With the Dow outperforming and Korean food/cosmetic names such as Korea Kolmar, Samyang Foods and Binggrae showing firm price action, the speaker sees early signs that global asset allocation may be rotating away from growth and semiconductor-led areas into previously ignored domestic staples; he frames this as a regime to monitor rather than a direct recommendation.
Lee Jae-kyu PB Deputy Manager, SK Securities 11:24
Samsung and SK Hynix dips buyable.
Samsung Electronics, SK Hynix and Samsung Electronics preferred remain buy-on-dip candidates; valuations and supply are supportive, and today's pullback is a buying opportunity for investors who do not own them, though the speaker warns against making them an extreme half-of-portfolio concentration.
Lee Jae-kyu PB Deputy Manager, SK Securities 20:35
KOSDAQ strength favors ETF exposure.
If KOSDAQ stays stronger than KOSPI through September 6, the speaker expects KOSDAQ strength could accelerate into year-end or the first half next year; ETF inflows into KOSDAQ names, policy support and a prior supply vacuum support interest, but he recommends ETF-based exposure over individual stock risk and would consider raising his KOSDAQ allocation from 35 percent to 40 percent only if it holds up.
Lee Jae-kyu PB Deputy Manager, SK Securities 26:03
ESS shortage makes Korean battery makers attractive.
Korean secondary battery names are very positive because ESS is becoming tied to AI data centers and national security; US restrictions on Chinese components may create shortages by 2027, benefiting Korean companies with US factories and vertical integration, while Tesla's recovery, EV momentum and oil volatility add demand; the speaker sees Samsung SDI as the leader and also flags LG Energy Solution, SK On, L&F and POSCO Future M as names to check, focusing on Samsung SDI and material and component names.
Lee Jae-kyu PB Deputy Manager, SK Securities 34:13
Hanmi Pharm has obesity and licensing drivers.
Hanmi Pharm is one of the few Korean pharma and biotech companies generating profits alongside Samsung Biologics and Celltrion; today's large licensing-out deal, expected second-half obesity drug sales and upcoming clinical data around year-end or October make it worth checking, with the key being how much revenue and operating profit the obesity drugs contribute.
Lee Jae-kyu PB Deputy Manager, SK Securities 35:35
US biotech strength may lift Korean pharma.
The US biotech index is showing better price action than the S&P 500, and the speaker believes Korean pharma and biotech may follow the strength; because individual names are hard to analyze and can gap on clinical news, he suggests ETF-based access to the Korean biotech and pharma complex.
Lee Jae-kyu PB Deputy Manager, SK Securities 36:14
Semiconductors still lead; lower tiers attractive.
Semiconductors are still the leading sector, and the speaker sees lower-tier semiconductor stocks as attractive for further upside; however, the main index trend support needs to hold because a break would indicate supply rather than valuation, so investors should confirm the support zone rather than chase blindly.
Up Next

This 3PRO TV (삼프로TV) video, published August 24, 2026, features Lee Jae-kyu discussing EWY, 161890.KS, 003230.KS, 005180.KS, 005930.KS, 005935.KS, 000660.KS, KOSDAQ Index, KOSDAQ, 006400.KS, 066970.KS, 003670.KS, 128940.KS, XBI, Korean biotech/pharma ETF, Korean semiconductor sector, Korean semiconductor materials/equipment. 8 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Lee Jae-kyu  · Tickers: EWY, 161890.KS, 003230.KS, 005180.KS, 005930.KS, 005935.KS, 000660.KS, KOSDAQ Index, KOSDAQ, 006400.KS, 066970.KS, 003670.KS, 128940.KS, XBI, Korean biotech/pharma ETF, Korean semiconductor sector, Korean semiconductor materials/equipment